Lamivudine therapy in chronic delta hepatitis

A multicentre randomized-controlled pilot study

G. A. Niro, A. Ciancio, H. L. Tillman, M. Lagget, A. Olivero, F. Perri, R. Fontana, N. Little, F. Campbell, A. Smedile, M. P. Manns, A. Andriulli, M. Rizzetto

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background: Delta virus (HDV)-related chronic hepatitis is difficult to treat. Aims: To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen sero-conversion. Methods: Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT > 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. Results: Twenty-five patients (81%) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11%) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43%) from group A and two of 12 patients (17%) from group B had a >2 point decrease in the Ishak necroinflammatory score. Conclusion: A sustained complete response was achieved in 8% of hepatitis D virus-infected patients treated with lamivudine and a partial histological response in 26% of them. Hepatitis D virus viraemia was unaffected, even in patients when hepatitis B virus replication was lowered by lamivudine therapy.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number3
DOIs
Publication statusPublished - Aug 1 2005

Fingerprint

Chronic Hepatitis D
Lamivudine
Hepatitis Delta Virus
Hepatitis B Surface Antigens
RNA
Therapeutics
Liver
Viremia
Chronic Hepatitis
Virus Replication
Alanine Transaminase
Hepatitis B virus
Liver Diseases
Histology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lamivudine therapy in chronic delta hepatitis : A multicentre randomized-controlled pilot study. / Niro, G. A.; Ciancio, A.; Tillman, H. L.; Lagget, M.; Olivero, A.; Perri, F.; Fontana, R.; Little, N.; Campbell, F.; Smedile, A.; Manns, M. P.; Andriulli, A.; Rizzetto, M.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 3, 01.08.2005, p. 227-232.

Research output: Contribution to journalArticle

Niro, GA, Ciancio, A, Tillman, HL, Lagget, M, Olivero, A, Perri, F, Fontana, R, Little, N, Campbell, F, Smedile, A, Manns, MP, Andriulli, A & Rizzetto, M 2005, 'Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study', Alimentary Pharmacology and Therapeutics, vol. 22, no. 3, pp. 227-232. https://doi.org/10.1111/j.1365-2036.2005.02542.x
Niro, G. A. ; Ciancio, A. ; Tillman, H. L. ; Lagget, M. ; Olivero, A. ; Perri, F. ; Fontana, R. ; Little, N. ; Campbell, F. ; Smedile, A. ; Manns, M. P. ; Andriulli, A. ; Rizzetto, M. / Lamivudine therapy in chronic delta hepatitis : A multicentre randomized-controlled pilot study. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 22, No. 3. pp. 227-232.
@article{995ad910c2b442cc8d99471c1876f257,
title = "Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study",
abstract = "Background: Delta virus (HDV)-related chronic hepatitis is difficult to treat. Aims: To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen sero-conversion. Methods: Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT > 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. Results: Twenty-five patients (81{\%}) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11{\%}) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43{\%}) from group A and two of 12 patients (17{\%}) from group B had a >2 point decrease in the Ishak necroinflammatory score. Conclusion: A sustained complete response was achieved in 8{\%} of hepatitis D virus-infected patients treated with lamivudine and a partial histological response in 26{\%} of them. Hepatitis D virus viraemia was unaffected, even in patients when hepatitis B virus replication was lowered by lamivudine therapy.",
author = "Niro, {G. A.} and A. Ciancio and Tillman, {H. L.} and M. Lagget and A. Olivero and F. Perri and R. Fontana and N. Little and F. Campbell and A. Smedile and Manns, {M. P.} and A. Andriulli and M. Rizzetto",
year = "2005",
month = "8",
day = "1",
doi = "10.1111/j.1365-2036.2005.02542.x",
language = "English",
volume = "22",
pages = "227--232",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Lamivudine therapy in chronic delta hepatitis

T2 - A multicentre randomized-controlled pilot study

AU - Niro, G. A.

AU - Ciancio, A.

AU - Tillman, H. L.

AU - Lagget, M.

AU - Olivero, A.

AU - Perri, F.

AU - Fontana, R.

AU - Little, N.

AU - Campbell, F.

AU - Smedile, A.

AU - Manns, M. P.

AU - Andriulli, A.

AU - Rizzetto, M.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Background: Delta virus (HDV)-related chronic hepatitis is difficult to treat. Aims: To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen sero-conversion. Methods: Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT > 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. Results: Twenty-five patients (81%) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11%) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43%) from group A and two of 12 patients (17%) from group B had a >2 point decrease in the Ishak necroinflammatory score. Conclusion: A sustained complete response was achieved in 8% of hepatitis D virus-infected patients treated with lamivudine and a partial histological response in 26% of them. Hepatitis D virus viraemia was unaffected, even in patients when hepatitis B virus replication was lowered by lamivudine therapy.

AB - Background: Delta virus (HDV)-related chronic hepatitis is difficult to treat. Aims: To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen sero-conversion. Methods: Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT > 1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A, n = 11) or lamivudine (group B, n = 20) for 52 weeks; thereafter, all patients were given lamivudine for 52 weeks and followed up for 16 weeks. Results: Twenty-five patients (81%) completed the study. No patient was HDV-RNA-negative at week 52; three patients (11%) were negative at week 104. Two of them remained HDV-RNA-negative at week 120, and one lost the hepatitis B surface antigen without seroconversion. Paired pre-treatment and week 104 liver biopsies were available from 19 patients: of which three of seven (43%) from group A and two of 12 patients (17%) from group B had a >2 point decrease in the Ishak necroinflammatory score. Conclusion: A sustained complete response was achieved in 8% of hepatitis D virus-infected patients treated with lamivudine and a partial histological response in 26% of them. Hepatitis D virus viraemia was unaffected, even in patients when hepatitis B virus replication was lowered by lamivudine therapy.

UR - http://www.scopus.com/inward/record.url?scp=23844439919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844439919&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02542.x

DO - 10.1111/j.1365-2036.2005.02542.x

M3 - Article

VL - 22

SP - 227

EP - 232

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -